Research ArticleCancer

Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy

See allHide authors and affiliations

Science Translational Medicine  28 Feb 2018:
Vol. 10, Issue 430, eaao2731
DOI: 10.1126/scitranslmed.aao2731

A CAR to drive out glioblastoma

T cells with chimeric antigen receptors (CARs) targeting individual tumor antigens can be a very effective form of immunotherapy, but they only work when tumor cells express the target antigens. This presents a problem for tumors like glioblastoma, where the expression of potential targets is generally heterogeneous. However, Pellegatta et al. have identified a protein called chondroitin sulfate proteoglycan 4 (CSPG4), which is present on 67% of glioblastomas and induced by glial cells surrounding the tumor. The authors showed that targeting CSPG4 with CAR-T cells effectively treats glioblastoma in mouse models, with no evidence of antigen loss resulting in tumor escape.

View Full Text

Stay Connected to Science Translational Medicine